XCath Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
XCath General Information
Description
Developer of advanced endovascular robotics and steerable guidewires designed to enhance precision in navigating the vascular system. The company offers tools for minimally invasive treatment of complex vascular conditions, enabling doctors to improve clinical outcomes, ensure safer procedures, and achieve faster recovery times.
Contact Information
Website
www.xcath.comCorporate Office
- 9330 Kirby Drive
- Suite 900
- Houston, TX 77054-2595
- United States
Corporate Office
- 9330 Kirby Drive
- Suite 900
- Houston, TX 77054-2595
- United States
XCath Timeline
XCath Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 01-Jun-2026 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series C) | 12-Mar-2026 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC | Completed | Clinical Trials - Phase 1 | ||||
| 2. Later Stage VC (Series B) | 20-Jan-2022 | $24M | $29.3M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 08-Mar-2017 | $5.33M | $5.33M | Completed | Clinical Trials - Phase 1 |
XCath Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-5 | ||||||||
| Series B-4 | ||||||||
| Series B-3 | ||||||||
| Series B-2 | ||||||||
| Series B-1 | 9,100,000 | $0.000010 | $0.55 | $0.55 | 1x | $0.55 | 14.12% | |
| Series A | 13,257,203 | $0.000010 | $0.4 | $0.4 | 1x | $0.4 | 20.57% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
XCath Patents
XCath Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026159544-A1 | Method of guiding catheter and guiding device | Pending | 23-Jan-2025 | ||
| WO-2026150301-A1 | System for guiding intravascular insertion device | Pending | 08-Jan-2025 | ||
| WO-2026146380-A1 | Method for providing graphic user interface displaying cassette driving module, and graphic user interface | Pending | 02-Jan-2025 | ||
| WO-2026120520-A1 | Guide wire-driving cassette | Pending | 04-Dec-2024 | ||
| WO-2026053015-A1 | Module for guiding at least one of guidewire or catheter | Pending | 06-Sep-2024 |
XCath Signals
XCath Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Crescent Enterprises | Corporation | Minority | ||
| Angel (individual) | Minority |
XCath FAQs
-
When was XCath founded?
XCath was founded in 2017.
-
Where is XCath headquartered?
XCath is headquartered in Houston, TX.
-
What is the size of XCath?
XCath has 50 total employees.
-
What industry is XCath in?
XCath’s primary industry is Surgical Devices.
-
Is XCath a private or public company?
XCath is a Private company.
-
What is XCath’s current revenue?
The current revenue for XCath is .
-
How much funding has XCath raised over time?
XCath has raised $95.4M.
-
Who are XCath’s investors?
Crescent Enterprises and have invested in XCath.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process